19745-07-4

Usage

Chemical Properties

Colorless liquid

InChI:InChI=1/C4H2Cl2N2/c5-3-1-7-4(6)2-8-3/h1-2H

Upstream product

• 6863-76-9 3-chloropyrazine 1-oxide 
• 14508-49-7 2-chloropyrazin 
• 290-37-9 1,4-pyrazine 
• 374063-92-0 2-hydroxy-5-bromopyrazine 
• 89180-45-0 5-chloropyrazine-2-ol 
• 33332-29-5 2-amino-5-chloropyrazine 
• 7732-18-5 water 
• 7782-50-5 chlorine 
• 89180-45-0 5-chloro-1,2-dihydro-2-oxopyrazine 

Downstream Products

• 123903-93-5 3-[(5-Chloro-pyrazin-2-ylamino)-methyl]-5-(2-fluoro-phenyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 426829-52-9 tert-Butyl 4-(6-Chloro-2-Pyrazinyl)-1-Piperazinecarboxylate 
• 299441-13-7 (5-chloropyrazin-2-yl)hydrazine 
• 84445-51-2 5'-chloro-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl 
• 1078166-47-8 1-Benzoyl-3-{[(5-chloropyrazin-2-yl)oxy]methyl}azetidine-3-carboxylic acid 
• 1174517-66-8 4-(3,6-dichloro-pyrazin-2-yl)-benzoic acid ethyl ester 
• 76849-85-9 2-chloro-5-(4-methoxyphenyl)pyrazine 
• 866939-13-1 1,1-dimethylethyl 7-[(5-chloro-2-pyrazinyl)oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 1245215-80-8 N-(5-chloropyrazin-2-yl)-N-methyl ethanesulfonamide 
• 76849-86-0 2-chloro-5-(4-phenoxyphenyl)pyrazine 
• 1357172-39-4 C₅H₂Cl₂N₂O 
• 1388144-55-5 ethyl [1-(5-chloropyrazin-2-yl)piperidin-4-yl]acetate 
• 1023813-21-9 3,6-dichloropyrazine-2-carboxamide 
• 1562104-45-3 C₃₈H₃₈F₄N₄O₂ 

Relevant academic research and scientific papers

Favipiravir intermediate and synthesis method of favipiravir

The invention discloses a favipiravir intermediate and a synthesis method of favipiravir. The synthesis method comprises the following steps: taking 2,5-dihalopyrazine as an initial raw material, reacting 2,5-dihalopyrazine with formamide under the action of an oxide and a catalyst to generate 6-halo-3-chloro-2-amide pyrazine; carrying out a reaction on 6-halo-3-chloro-2-amide pyrazine under the action of a dehydration chlorinating agent and an acid-binding agent to generate a favipiravir intermediate 3,6-dichloro-3-cyanopyrazine; carrying out an aromatic ring fluorination reaction on the obtained favipiravir intermediate and potassium fluoride in dimethyl sulfoxide to generate 3,6-difluoro-3-cyanopyrazine; adding the 3,6-difluoro-3-cyanopyrazine into a water solution containing sodium acetate, and carrying out hydrolysis to obtain 6-fluoro-3-hydroxyl-2-cyanopyrazine; and finally, carrying out a cyano hydrolysis reaction to obtain favipiravir. A mixture of 2,5-dichloropyrazine and 2-chloro-5-bromopyrazine are used as raw materials to synthesize the favipiravir intermediate, the raw material cost is remarkably reduced, and the provided synthesis method has the technical advantages of high yield and low cost.

NOVEL COMPOUNDS AS GPR119 AGONISTS

The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

Bipiperidinyl compounds of the formula I, are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

AMIDOPYRAZOLE DERIVATIVE

A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.

Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders

Aryl sulfonamide and sulfonyl compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

TERTRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS

The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

BENZO ‘ D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

The present invention relates to benzazepine derivatives of formula ( I ) wherein: R1 represents -C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

Studies on Pyrazines. 29. High Regioselective Synthesis of Chloropyrazines from 3-Substituted Pyrazine 1-Oxides

Reaction of 3-methoxy- or 3-chloropyrazine 1-oxides with refluxing phosphoryl chloride in the presence of amine led to a high regioselective formation of 3-substituted 2-chloropyrazines.In contrast, the use of chloroacetyl chloride instead of phosphoryl chloride enabled different regioselectivity to yield 6-substituted 2-chloropyrazines, particularly 3-methoxycarbonylpyrazine 1-oxide was almost exclusively converted into methyl 6-chloropyrazinecarboxylate under conditions without the amine.